Frevert J - Search Results

1

Complexing Protein-Free Botulinum Neurotoxin A Formulations: Implications of Excipients for Immunogenicity.

Martin MU, Frevert J, Tay CM. Martin MU, et al. Among authors: frevert j. Toxins (Basel). 2024 Feb 10;16(2):101. doi: 10.3390/toxins16020101. Toxins (Basel). 2024. PMID: 38393178 Free PMC article. Review.

2

The immunology of botulinum toxin therapy: A brief summary.

Dressler D, Bigalke H, Frevert J. Dressler D, et al. Among authors: frevert j. Toxicology. 2022 Nov;481:153341. doi: 10.1016/j.tox.2022.153341. Epub 2022 Sep 30. Toxicology. 2022. PMID: 36191878 Review.

3

Immunogenicity Associated with Aesthetic Botulinumtoxin A: A Survey of Asia-Pacific Physicians' Experiences and Recommendations.

Park JY, Corduff N, Frevert J, Wanitphakdeedecha R, Chao YYY. Park JY, et al. Among authors: frevert j. Plast Reconstr Surg Glob Open. 2022 Apr 18;10(4):e4217. doi: 10.1097/GOX.0000000000004217. eCollection 2022 Apr. Plast Reconstr Surg Glob Open. 2022. PMID: 35450268 Free PMC article.

4

Neurotoxin Impurities: A Review of Threats to Efficacy.

Park JY, Sunga O, Wanitphakdeedecha R, Frevert J. Park JY, et al. Among authors: frevert j. Plast Reconstr Surg Glob Open. 2020 Jan 24;8(1):e2627. doi: 10.1097/GOX.0000000000002627. eCollection 2020 Jan. Plast Reconstr Surg Glob Open. 2020. PMID: 32095419 Free PMC article.

5

IncobotulinumtoxinA: A Highly Purified and Precisely Manufactured Botulinum Neurotoxin Type A.

Kerscher M, Wanitphakdeedecha R, Trindade de Almeida A, Maas C, Frevert J. Kerscher M, et al. Among authors: frevert j. J Drugs Dermatol. 2019 Jan 1;18(1):52-57. J Drugs Dermatol. 2019. PMID: 30681794 Review.

6

Comparison of botulinum neurotoxin type A formulations in Asia.

Frevert J, Ahn KY, Park MY, Sunga O. Frevert J, et al. Clin Cosmet Investig Dermatol. 2018 Jul 5;11:327-331. doi: 10.2147/CCID.S160723. eCollection 2018. Clin Cosmet Investig Dermatol. 2018. PMID: 30013379 Free PMC article.

7

Rational design of botulinum neurotoxin A1 mutants with improved oxidative stability.

López de la Paz M, Scheps D, Jurk M, Hofmann F, Frevert J. López de la Paz M, et al. Among authors: frevert j. Toxicon. 2018 Jun 1;147:54-57. doi: 10.1016/j.toxicon.2017.10.011. Epub 2017 Oct 16. Toxicon. 2018. PMID: 29042311

8

Design of modified botulinum neurotoxin A1 variants with a shorter persistence of paralysis and duration of action.

Scheps D, López de la Paz M, Jurk M, Hofmann F, Frevert J. Scheps D, et al. Among authors: frevert j. Toxicon. 2017 Dec 1;139:101-108. doi: 10.1016/j.toxicon.2017.09.006. Epub 2017 Sep 13. Toxicon. 2017. PMID: 28918229

9

Response to Commentary by W. Jost on: Pharmaceutical, Biological, and Clinical Properties of Botulinum Neurotoxin Type A Products.

Frevert J. Frevert J. Drugs R D. 2015 Jun;15(2):217-8. doi: 10.1007/s40268-015-0091-y. Drugs R D. 2015. PMID: 25851380 Free PMC article. No abstract available.

10

Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products.

Frevert J. Frevert J. Drugs R D. 2015 Mar;15(1):1-9. doi: 10.1007/s40268-014-0077-1. Drugs R D. 2015. PMID: 25559581 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

38 results

Search Page